RNAC
Cartesian Therapeutics Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$163.03M
P/E Ratio
—
EPS
$-5.02
Beta
0.56
52W High
$15.57
52W Low
$5.60
50-Day MA
$6.95
200-Day MA
$8.85
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
25.06
PEG Ratio
0.00
About Cartesian Therapeutics Inc.
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company is headquartered in Watertown, Massachusetts.
Fundamentals
| Revenue (TTM) | $2.80M |
| Gross Profit (TTM) | $-55.24M |
| EBITDA | $-83.75M |
| Operating Margin | -2317.00% |
| Return on Equity | -7029.00% |
| Return on Assets | -14.80% |
| Revenue/Share (TTM) | $0.11 |
| Book Value | $-4.85 |
| Price-to-Book | 31.26 |
| Price-to-Sales (TTM) | 58.29 |
| EV/Revenue | 19.12 |
| EV/EBITDA | 1.77 |
| Quarterly Earnings Growth (YoY) | -7.40% |
| Quarterly Revenue Growth (YoY) | 16.80% |
| Shares Outstanding | $26.51M |
| Float | $6.82M |
| % Insiders | 59.53% |
| % Institutions | 28.00% |
Analyst Ratings
Consensus ($35.57 target)
1
Strong Buy7
Buy1
HoldData last updated: 4/9/2026